Uninapin Tablets (Terbinafine Hydrochloride)
Terbinafine Hydrochloride
Prescription medication
Kujoo Pharmaceutical Co., Ltd.
MFDS item code 200403039 · Notified 2004.08.09
This product's status changed to Expired on 2023.04.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of onychomycosis, dermatomycosis (such as tinea pedis and tinea corporis), and tinea capitis
This medication is used to treat skin mycosis such as tinea pedis, tinea corporis, and tinea cruris in adults. It is also used to treat tinea capitis in children.
Administer 125 mg of terbinafine per dose twice daily, or 250 mg per dose once daily. The treatment duration depends on the condition, as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris (jock itch): 2~4 weeks 2) Onychomycosis Treatment is usually given for 6 weeks~3 months. The treatment period may be shortened to 3 months or less for infection of a fingernail or a relatively small toenail, or in younger patients. Three months is usually sufficient for treatment of toenail infections, although some patients may require 6 months or longer. Treatment may need to be longer in patients whose toenails grow slowly. Reduce the daily dose by 1/2 in patients with creatinine clearance below 50 mL/min.
Administer to children aged 2 years and older. Use is not recommended in children under 2 years of age because there is no experience with its use in this age group. Tinea capitis: 4 weeks Tinea capitis occurs primarily in children. To prevent recurrence of infection, treatment should be given regularly and appropriately for the prescribed duration. Body weight below 20 kg (under 5 years): administer 62.5 mg per dose once daily. Because experience with treatment is limited, decide whether to administer the drug after considering the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): administer 125 mg per dose once daily. Body weight over 40 kg (over 12 years): administer 250 mg per dose once daily.
This medication is not recommended for patients with liver problems or a history of liver disease. Liver function tests should be performed before use, and liver function should be monitored regularly during treatment. If symptoms of liver dysfunction occur, discontinue use immediately and consult a doctor. This medication should not be used in patients with severe blood disorders or significantly impaired kidney function, children under 2 years of age, or nursing mothers. Additionally, individuals with allergies to this medication should not take it. Special caution is required for elderly patients or children with low body weight when using this medication. If severe skin rash or allergic reactions occur, discontinue use immediately. This medication is primarily metabolized in the liver, so individuals with weak liver or kidney function should use it after consulting a doctor. Dizziness or drowsiness may occur while taking this medication, so it is advisable to avoid driving or operating machinery. There may be interactions with other medications, so if you are taking other medications, be sure to inform your doctor or pharmacist. Women who are pregnant or may become pregnant should thoroughly consult with their doctor regarding the use of this medication, and nursing mothers should avoid taking it. Overdose may result in headaches, nausea, abdominal pain, and dizziness, and if these symptoms occur, seek medical attention immediately. This medication should be stored out of the reach of children, protected from direct sunlight, and kept at room temperature.
Liver and biliary failure, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, fatigue, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, vesicular dermatitis, psoriatic rash, worsening of psoriasis, hair loss, musculoskeletal reaction, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangitis, abdominal distension, decreased appetite, dyspepsia, nausea, mild abdominal pain, diarrhea, gastric discomfort, thirst, vomiting, glossitis, depression, anxiety, headache, taste disturbance, dizziness, drowsiness, sensory abnormalities, sensory loss, decreased attention, insomnia, elevated BUN, polyuria, visual impairment, tinnitus, anaphylactic-like reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol in the blood, elevated triglycerides, fatigue, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, vision deterioration, hearing loss, auditory impairment, vasculitis, permanent loss of smell, hyposmia, olfactory dysfunction, drug rash accompanied by eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased serum creatine phosphokinase.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air or moisture from entering, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain its effectiveness for a longer period.
White to whitish round tablets
In-house packaging unit
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Terbinafine Hydrochloride
Prescription medication
Kujoo Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
GP Therapeutics Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Hutex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Anguk Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Medica Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Gyeongnam Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Daehwa Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.